triflusal has been researched along with Infarction, Middle Cerebral Artery in 2 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 2 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Amtul, Z; Cechetto, DF; Haque, W | 1 |
| Choi, KJ; Kim, SW; Lee, JK; Park, JY; Yoon, SH | 1 |
2 other study(ies) available for triflusal and Infarction, Middle Cerebral Artery
| Article | Year |
|---|---|
Dipyridamole plus Triflusal versus Triflusal Alone in Infarct Reduction after Middle Cerebral Artery Occlusion.
Topics: Animals; Brain; Cytoprotection; Dipyridamole; Disease Models, Animal; Dose-Response Relationship, Drug; Drug Therapy, Combination; Infarction, Middle Cerebral Artery; Male; Neuroprotective Agents; Rats, Wistar; Salicylates | 2018 |
Neuroprotective effect of triflusal and its main metabolite, 2-hydroxy-4-trifluoromethylbenzoic acid (HTB), in the postischemic brain.
Topics: Animals; Anti-Inflammatory Agents; Aspirin; Brain; Brain Ischemia; Cytokines; Infarction, Middle Cerebral Artery; Male; Neurons; Neuroprotective Agents; Rats, Sprague-Dawley; Salicylates | 2017 |